Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic ...

Camrelizumab is under clinical development by Elevar Therapeutics and currently in Pre-Registration for Hepatocellular Carcinoma.

Tevimbra is already approved in the US for the treatment of unresectable or metastatic oesophageal squamous cell carcinoma ...

Tevimbra is under clinical development by BeiGene and currently in Phase III for Hepatocellular Carcinoma. According to GlobalData, Phase III drugs for Hepatocellular Carcinoma have a 47% phase ...

Now, China-based CARsgen has shared pivotal results from the latter portion of a phase 1/2 study evaluating the therapy for ...

Patients on the Tevimbra combo had a 20 percent reduction in risk of death compared to those on chemotherapy alone.

CARsgen Therapeutics' claudin 18.2-targeting autologous CAR-T therapy satricabtagene autoleucel (satri-cel) has shown efficacy in gastric cancer, in a rare win for this type of cell therapy in a solid ...

More research is needed to refine treatment strategies and identify predictive biomarkers for patient selection, according to researchers.

San Mateo, California Monday, December 30, 2024, 18:00 Hrs [IST] ...

Background and objective Gastric cancer (GC) remains a prevalent and preventable disease, yet accurate early diagnostic ...

FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

INR:2435. charminar satta chart 2022 Review of clinical developments of China's Class 1 new drugs in February 2020 Tumor Therapeutic Fields + Chemother ...